Dermoscopy for the Differentiation of Subacute Cutaneous Lupus Erythematosus from Other Erythematous Desquamative Dermatoses-Psoriasis, Nummular Eczema, Mycosis Fungoides and Pityriasis Rosea. [PDF]
J Clin MedSubacute cutaneous lupus erythematosus (SCLE) is a condition that might pose a diagnostic challenge. The aim of this study was to assess the usefulness of videodermoscopy in the differentiation of SCLE from other erythematous-desquamative dermatoses ...
Żychowska M, Kołcz K.
europepmc +2 more sources
The significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations. [PDF]
Dermatol Ther, 2022 The article by Martora F. et al. on a series of patients with pityriasis rosea (PR) after Moderna COVID-19 vaccine 1 recently published in your journal prompted us to make some observations.
Ciccarese G, Parodi A, Drago F.
europepmc +2 more sources
Pityriasis Rosea Induced by COVID-19 Vaccination. [PDF]
Eur J Case Rep Intern Med, 2022 It is increasingly recognized that SARS-CoV-2 infection and COVID-19 vaccines have been associated with skin disorders, including pityriasis rosea. It has been reported that pityriasis rosea has been triggered by several vaccines, as a rare side-effect ...
Khattab E, Christaki E, Pitsios C.
europepmc +2 more sources
Domperidone-induced pityriasis rosea-like drug eruption. [PDF]
Clin Case Rep, 2022 Pityriasis rosea is a common, acute, self limiting inflammatory skin disease. Pityriasis rosea‐like eruptions (PR‐LE) have been reported after drugs. The clinical presentation of PR‐LE can be distinguished from pityriasis rosea.
Saad S +3 more
europepmc +2 more sources
Association between Pityriasis Rosea (PR) and HHV-6/HHV-7 Infection: Importance of Sample Selection and Diagnostic Techniques. [PDF]
Diagnostics (Basel)Recent studies have focused on the role of human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7) in PR etiology with varying results. In our study, with the approach that the discrepancy between the results may be related to the different samples ...
Aydin Kurc M +5 more
europepmc +2 more sources
COVID-19-associated pityriasis rosea in children: Case report and literature review. [PDF]
Clin Case Rep, 2022 Skin lesions are one of the Coronavirus disease 2019 (COVID‐19) symptoms. Pityriasis rosea (PR) is a mucocutaneous manifestation that can occur following virus infections. Most of the PR lesions after COVID‐19 infection were reported in adults.
Khalili M +3 more
europepmc +2 more sources
Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. [PDF]
Dermatol Reports, 2023 Only a few cases of pityriasis rosea (PR)/pityriasis rosea-like eruption (PRLE) after anti-SARS-CoV-2 vaccination have been reported. In the period May 2021- February 2022 we observed five cases of clinically typical PR that appeared 2 to 3 weeks after ...
Veraldi S +3 more
europepmc +2 more sources
Pityriasis Rosea Following Pfizer-BioNTech Vaccination in an Adolescent Girl. [PDF]
Cureus, 2022 Pityriasis rosea (PR) is an acute self-limiting exanthematous skin disorder characterized by the presence of a primary solitary lesion called a herald patch and the subsequent development of diffuse papulosquamous lesions within 1 to 2 weeks.
Bin Rubaian NF +3 more
europepmc +2 more sources
InnovAiT: Education and inspiration for general practicePityriasis rosea is a benign self-limiting rash, usually lasting 6 to 8 weeks. In classic pityriasis rosea a ‘herald patch’ is the initial finding, a large oval patch usually found on the torso.
Litchman G, Nair PA, Syed HA, Le JK.
europepmc +2 more sources
Dupilumab-induced pityriasis rosea. [PDF]
JAAD Case Rep, 2023 Zabel M +5 more
europepmc +2 more sources